Fragment 176-191

Origin and Structure

Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal residues 176-191 of human growth hormone. The interest in this specific fragment began in the 1990s with work at Monash University by Frank Ng and colleagues, who reported that the lipolytic activity of hGH appeared to reside in the C-terminal region, separable from the anterior portions of the molecule that drive IGF-1 elevation and the diabetogenic effects characteristic of full-length GH. That observation underpinned an attempt to develop a "fat-loss-only" GH derivative that would promote lipolysis without the anabolic or glucoregulatory consequences of systemic GH administration.

The pharmaceutical development that emerged from this line of research was AOD-9604, a closely related modified version of the C-terminal fragment advanced by Metabolic Pharmaceuticals into clinical trials in the early 2000s. The "Fragment 176-191" sold as a research chemical is the unmodified base fragment; AOD-9604 carries an additional N-terminal tyrosine. The two are often conflated in community literature but are distinct molecules with overlapping but not identical pharmacology.

Mechanism of Action

Fragment 176-191 is proposed to act independently of the growth hormone receptor. The mechanistic hypothesis, developed largely in rodent adipocyte work, is that the fragment stimulates lipolysis through beta-3 adrenergic receptor-related signaling and inhibits lipogenesis by interfering with fatty-acid synthesis in adipose tissue. Unlike intact GH, the fragment does not elevate IGF-1, does not produce measurable insulin resistance, and does not promote linear growth — properties that, if they hold in humans, would represent a genuinely distinctive profile within the GH-adjacent category.

Clinical Evidence and the AOD-9604 Story

AOD-9604 is the most informative clinical story here. Metabolic Pharmaceuticals advanced the compound through Phase 2 trials for obesity, with the pivotal study — a 12-week, placebo-controlled trial in obese adults reported in 2007 — failing to demonstrate clinically meaningful weight loss beyond placebo. The obesity program was effectively abandoned after that readout. AOD-9604 was subsequently granted GRAS (Generally Recognized As Safe) status by the FDA in 2014 for use as a food ingredient but has not been approved as a therapeutic agent for any indication.

For Fragment 176-191 specifically:

• No Phase 3 clinical trials exist. The evidence base is rodent lipolysis work, adipocyte-culture studies, and the adjacent AOD-9604 trial program.
• Human bioavailability and dose-response data are sparse. Most of what is discussed in community contexts is extrapolated from AOD-9604 pharmacokinetics.
• No regulator has approved Fragment 176-191 for therapeutic use.

Anyone weighing the compound should understand that the closest thing to a clinical trial in this story — Metabolic's obesity program — did not succeed at its endpoint. The hypothesis that "GH lipolysis without GH side effects" would translate into meaningful weight loss in humans has not been clinically validated.

Practical Considerations

Research-use subcutaneous protocols typically use 250-500 mcg per dose, once or twice daily, fasted. Pre-workout or early-morning fasted dosing is the common pattern, on the theory that elevated catecholamines and low circulating glucose favor the lipolytic effect. Cycle lengths in community protocols are usually 8-12 weeks, often stacked alongside GHRP/GHRH combinations that drive the anabolic axis while Fragment 176-191 is used for its proposed targeted lipolysis — though no head-to-head or combination human trial has validated that logic.

Safety and Regulatory Status

Reported side effects in community use and in the AOD-9604 trial program are mild: injection-site reactions, occasional mild headache, transient drowsiness, and rare numbness at the injection site. Because Fragment 176-191 does not meaningfully elevate IGF-1 or insulin resistance markers at standard doses in published work, the characteristic GH-class concerns (carpal tunnel, joint stiffness, impaired glucose tolerance) are not prominent signals — though long-term human safety data is essentially absent.

Fragment 176-191 is not FDA-approved for any therapeutic indication. It is not a separately listed item on the WADA prohibited list but would be captured under the S2 class as a GH-related peptide. For broader context on fat-loss peptides and where this compound sits relative to other tools, see our coverage of tesamorelin (the FDA-approved GHRH analogue with clinically demonstrated visceral fat reduction) and the recovery peptide guide.